Lysholm J, Weitoft T
Department of Rheumatology, Falu Central Hospital, Falun, Sweden.
Scand J Rheumatol. 1988;17(6):465-8. doi: 10.3109/03009748809098808.
Drug withdrawal rate and reasons for treatment termination were studied in a retrospective life-table analysis of patients with rheumatoid arthritis prescribed Proresid, a semisynthetic podophyllotoxin derivative. Two years after starting with Proresid medication, half of the patients were still on treatment. After 5 years the termination rate had risen to 71%. Gastrointestinal side effects were the most common reason for abandoning medication. The results are compared with those found in other studies of similar desing. It is concluded that Proresid is a valuable and well-tolerated disease-modifying drug for long-term treatment of rheumatoid Arthritis.
在一项对服用半合成鬼臼毒素衍生物Proresid的类风湿性关节炎患者的回顾性生命表分析中，研究了药物戒断率和治疗终止原因。开始服用Proresid药物两年后，一半的患者仍在接受治疗。5年后，终止率升至71%。胃肠道副作用是停药的最常见原因。将结果与其他类似设计的研究结果进行了比较。得出的结论是，Proresid是一种用于类风湿性关节炎长期治疗的有价值且耐受性良好的改善病情药物。
